Telix Pharmaceuticals Limited의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Telix Pharmaceuticals Limited은 수익성이 있나요?
Telix Pharmaceuticals Limited에 부채가 있나요?
Telix Pharmaceuticals Limited의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$7.35
시가
$7.4
일일 범위
$7.3 - $7.55
52주 범위
$6.95 - $24.85
거래량
200
평균 거래량
2.5K
EPS(TTM)
0.02
배당수익률
--
시가총액
$2.4B
Telix Pharmaceutical Ltd.란 무엇인가요?
Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.